About ACADIA Pharmaceuticals Inc. - Common Stock (ACAD)
Acadia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapeutics to address unmet medical needs in central nervous system disorders. The company specializes in creating treatments for conditions such as schizophrenia and Parkinson's disease, leveraging its expertise in neuroscience to enhance the quality of life for patients. Through a combination of research, clinical development, and regulatory advocacy, Acadia aims to deliver targeted therapies that address the root causes of these complex conditions, while striving to improve overall patient outcomes in the neurological space. Read More
ACADIA Pharmaceuticals (ACAD) shows strong growth momentum and technical setup, with surging EPS, revenue, and a high technical grade for potential breakout.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Citi’s 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 9:45 a.m. Eastern Time.
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) breached their fiduciary duties to shareholders.
ACADIA Pharmaceuticals offers strong growth and profitability at a reasonable industry valuation, making it a prime candidate for affordable growth investors.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 5, 2025, at 4:30 p.m. Eastern Time.
Boston, MA – October 3, 2025 – Leap Therapeutics, Inc. (NASDAQ: LPTX) experienced a sharp downturn in its stock performance today, with shares falling by over 20% in intraday trading. This significant decline marks a notable correction for the biotechnology company, which had seen its stock surge dramatically in the preceding days,
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced one late-breaker oral platform presentation and two poster presentations to be presented at the International Congress of Parkinson’s Disease and Movement Disorders® being held October 5-9, 2025, in Honolulu, Hawaii.
In the preceding three months, 11 analysts have released ratings for ACADIA Pharmaceuticals (NASDAQ: ACAD), presenting a wide array of perspectives from bullish to bearish.
Discover ACADIA PHARMACEUTICALS (ACAD), a strong affordable growth stock with impressive earnings, solid financials, and a reasonable valuation in the biotech sector.
Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook.
